The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*
Abstract
BACKGROUND: Venous thromboembolic disease in the form of deep venous thrombosis and pulmonary embolism is a major risk after a total hip arthroplasty. Enoxaparin, a low-molecular-weight heparin, has been shown to reduce the prevalence of deep venous thrombosis after total hip arthroplasty. Warfarin, an orally administered anticoagulant, has been used historically to reduce the risk of deep venous thrombosis after total hip arthroplasty. METHODS: We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty. We also evaluated the prevalence of complications and mortality from venous thromboembolic disease within three months after discharge. RESULTS: Three thousand and eleven patients at 156 centers were randomly assigned to prophylactic treatment with injection of enoxaparin or oral administration of adjusted-dose warfarin during hospitalization. During the study, fifty-five (3.6 percent) of the 1516 patients who were managed with enoxaparin and fifty-six (3.7 percent) of the 1495 patients who were managed with warfarin had venous thromboembolic disease. Twenty-one patients (0.7 percent), which included four (0.3 percent) of those managed with enoxaparin and seventeen (1.1 percent) of those managed with warfarin (p = 0.0083), had venous thromboembolic disease during hospitalization. After discharge from the hospital, venous thromboembolic disease developed in ninety patients (3.0 percent): fifty-one (3.4 percent) of those managed with enoxaparin and thirty-nine (2.6 percent) of those managed with warfarin. One patient who had been managed with enoxaparin died because of a pulmonary embolism, which was confirmed at autopsy. Three additional patients (one who had been managed with enoxaparin and two who had been managed with warfarin) died, and the deaths were attributed to venous thromboembolic disease; however, no autopsies were performed. Twenty-six patients (0.9 percent) (eighteen managed with enoxaparin and eight managed with warfarin) had clinically important bleeding. CONCLUSIONS: Inpatient programs providing treatment with either enoxaparin (thirty milligrams every twelve hours) or adjusted-dose warfarin for a mean of 7.3 days afforded protection against venous thromboembolic disease, with overall rates of morbidity and mortality of 3.7 and 0.6 percent, respectively, and a very low rate of major bleeding complications (0.9 percent) for three months after total hip arthroplasty. During hospitalization, the patients managed with enoxaparin had a lower rate of venous thromboembolic disease than those managed with adjusted-dose warfarin (p = 0.0083). This benefit was lost after the medication was discontinued, with no difference in the prevalences of venous thromboembolic disease between the two groups at three months after discharge from the hospital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationWarkentin, T. E., Levine, M. N., Hirsh, J., Horsewood, P., Roberts, R. S., Gent, M., & Kelton, J. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322003 · Cited by 2,328
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Hirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Hirsh, J., Dalen, J. E., Deykin, D., & Toller, L. (1992) · Chest · doi:10.1378/chest.102.4_supplement.337s · Cited by 558
Turpie, A. G. G., Levine, M., Hirsh, J., Carter, C. J., Jay, R. M., Powers, P. J., Andrew, M. E., Hull, R. D., & Gent, M. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610093151503 · Cited by 520
Prevention of Venous Thrombosis and Pulmonary Embolism
(1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380060070028 · Cited by 460
Bergqvist, D., Benoni, G., Björgell, O., Fredin, H., Hedlundh, U., Nicolas, S., Nilsson, P., & Nylander, G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609053351002 · Cited by 457
Planes, A., Vochelle, N., Darmon, J.-Y., Fagola, M., Bellaud, M., & Huet, Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01453-5 · Cited by 432
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationKahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Self-citation
Metadata
- Authors
- COLWELL, C. W., COLLIS, D. K., PAULSON, R., McCUTCHEN, J. W., BIGLER, G. T., LUTZ, S., & HARDWICK, M. E.
- Venue
- The Journal of Bone & Joint Surgery
- Published
- 1999-07
- Volume
- 81
- Issue
- 7
- Pages
- 932-40
- ISSN
- 0021-9355 (ISSN-L)
- OpenAlex
- W1916215700
- Cited by
- 300
- References
- 16
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*. https://app.cochat.ai/papers/10.2106/00004623-199907000-00005
- The paper
- COLWELL, C. W., COLLIS, D. K., PAULSON, R., McCUTCHEN, J. W., BIGLER, G. T., LUTZ, S., & HARDWICK, M. E. (1999). Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*. The Journal of Bone & Joint Surgery. https://doi.org/10.2106/00004623-199907000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.